Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) PT at $11.42

Health Catalyst, Inc. (NASDAQ:HCAT) has earned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $11.42.

HCAT has been the topic of several recent analyst reports. Piper Sandler dropped their price target on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 26th. Stephens lowered their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Canaccord Genuity Group restated a “buy” rating and set a $11.00 price target on shares of Health Catalyst in a research note on Tuesday, May 21st. Evercore ISI dropped their price objective on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. Finally, JPMorgan Chase & Co. raised their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th.

Insider Transactions at Health Catalyst

In related news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the transaction, the insider now directly owns 255,881 shares in the company, valued at $1,847,460.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, COO Daniel Lesueur sold 8,137 shares of Health Catalyst stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total transaction of $61,678.46. Following the transaction, the chief operating officer now owns 140,108 shares in the company, valued at approximately $1,062,018.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. The disclosure for this sale can be found here. Insiders sold a total of 34,037 shares of company stock worth $236,872 over the last 90 days. 2.70% of the stock is owned by insiders.

Institutional Trading of Health Catalyst

Several hedge funds and other institutional investors have recently modified their holdings of HCAT. Los Angeles Capital Management LLC acquired a new position in Health Catalyst during the 4th quarter worth approximately $108,000. Charles Schwab Investment Management Inc. raised its position in Health Catalyst by 19.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 521,362 shares of the company’s stock worth $4,828,000 after acquiring an additional 85,777 shares in the last quarter. Versor Investments LP lifted its position in shares of Health Catalyst by 150.0% in the fourth quarter. Versor Investments LP now owns 29,000 shares of the company’s stock valued at $269,000 after buying an additional 17,400 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in Health Catalyst by 437.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 253,368 shares of the company’s stock worth $2,346,000 after purchasing an additional 206,184 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Health Catalyst during the 4th quarter worth about $645,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $8.44 on Wednesday. Health Catalyst has a 12-month low of $5.42 and a 12-month high of $11.41. The firm has a market capitalization of $498.26 million, a P/E ratio of -4.56 and a beta of 1.31. The business has a 50 day simple moving average of $7.05 and a 200 day simple moving average of $6.90.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. The company had revenue of $75.90 million for the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.21) EPS. Research analysts anticipate that Health Catalyst will post -0.35 EPS for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.